AVADEL PHARMACEUTICALS (AVDL)

Noteworthy Thursday Option Activity: ROOT, AVDL, IGT

Which stocks are moving before the opening bell on Thursday?

Which stocks are moving before the opening bell on Thursday?

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and...

RSI Alert: Avadel Pharmaceuticals (AVDL) Now Oversold

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens – – 91% reported...

Notable Wednesday Option Activity: KSS, LULU, AVDL

AVDL Crosses Below Key Moving Average Level

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Noteworthy Thursday Option Activity: AEP, AVDL, NFLX

AVDL Stock Earnings: Avadel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

AVDL stock results show that Avadel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

AVDL Stock Earnings: Avadel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avadel Pharmaceuticals (NASDAQ:AVDL) just reported results for the second quart...

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results

-- Generated $41.5 million in net revenue from sales of LUMRYZ™ -- -- More than 1,900 patients on LUMRYZ as of June 30th -- -- First...

Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8

DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...

First Week of AVDL March 2025 Options Trading

Avadel Pharmaceuticals Becomes Oversold (AVDL)

Avadel Pharmaceuticals to Join Russell 3000® Index

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s...

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

AVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

AVDL stock results show that Avadel Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient...

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Pharmaceuticals Issues Statement On Patent Litigation

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from...

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31st,...

Avadel Pharmaceuticals (AVDL) Shares Cross Below 200 DMA

First Week of September 20th Options Trading For Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals estimates Q4 net product revenue of ~$19M (NASDAQ:AVDL)

Avadel Pharmaceuticals reports Q4 net product revenue of ~$19M and projects ~$28M for 2023.